

# MOLECULAR DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS



**BIO063C**  
**June 2015**

Jon Evans  
***Project Analyst***

ISBN: 1-62296-110-2



**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481 USA**  
**866-285-7215 (toll-free within the USA),**  
**or (+1) 781-489-7301**  
**[www.bccresearch.com](http://www.bccresearch.com)**  
**[information@bccresearch.com](mailto:information@bccresearch.com)**

## TABLE OF CONTENTS

| TOPIC   | PAGE NO. |
|---|----------|
| CHAPTER 1 INTRODUCTION  | 2        |
| STUDY GOALS AND OBJECTIVES  | 2        |
| REASONS FOR DOING THE STUDY   | 2        |
| SCOPE OF REPORT   | 2        |
| INTENDED AUDIENCE   | 2        |
| METHODOLOGY AND INFORMATION SOURCES   | 3        |
| ANALYST'S CREDENTIALS   | 3        |
| RELATED BCC RESEARCH REPORTS  | 3        |
| BCC RESEARCH WEBSITE  | 4        |
| DISCLAIMER  | 4        |
| CHAPTER 2 SUMMARY   | 6        |
| FORECASTS   | 6        |
| <i>SUMMARY TABLE GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)</i>      | 6        |
| <i>SUMMARY FIGURE GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY, 2012-2020 (\$ MILLIONS)</i>        | 6        |
| VENDORS   | 7        |
| CHAPTER 3 OVERVIEW  | 9        |
| OVERVIEW  | 9        |
| INTRODUCTION TO GENOMIC DIAGNOSTICS   | 9        |
| EXPRESSION PROFILING AND DISEASE  | 11       |
| EXPRESSION PROFILING AND INFECTIOUS DISEASE   | 12       |
| DNA SEQUENCING FOR GENOTYPING AND DIAGNOSIS   | 12       |
| CLINICAL PHARMACOLOGY   | 13       |
| MUTATION DETECTION AND GENOTYPING FOR SPECIFIC GENES  | 13       |
| IDENTIFICATION OF NEW DISEASE GENES   | 13       |
| CHAPTER 4 REGULATIONS AND FINANCE   | 15       |
| OVERVIEW  | 15       |
| INSURANCE   | 15       |
| FOOD AND DRUG ADMINISTRATION GUIDELINES   | 16       |
| INTERNAL STANDARDS FOR DNA DIAGNOSTICS  | 17       |
| <i>TABLE 1 MINIMUM INFORMATION ABOUT A MICROARRAY EXPERIMENT - MIAME 2.0</i>                                | 18       |
| <i>TABLE 2 MICROARRAY QUALITY CONTROL (MAQC) PROJECT</i>  | 19       |
| CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA)   | 20       |
| <i>TABLE 3 U.S. LABORATORIES CLIA-CERTIFIED FOR MOLECULAR DIAGNOSTICS AND NUMBER OF DISEASE TESTS, 2012</i> | 21       |
| <i>FIGURE 1 GROWTH IN CLINICAL LABORATORY SITES AND DISEASE TESTING, 1993-2015</i>                          | 21       |
| <i>TABLE 4 GENETIC TESTING PROCEDURES PERFORMED IN U.S. BY TYPE, 2015</i>                                   | 22       |
| PERSONALIZED MEDICINES AND COMPANION DIAGNOSTICS  | 23       |
| FDA GUIDELINES FOR IN VITRO COMPANION DIAGNOSTICS   | 24       |
| Definition and Use of an IVD Companion Diagnostic Device  | 24       |

| <b>TOPIC</b>  | <b>PAGE NO.</b> |
|---|-----------------|
| Review and Approval of IVD Companion Diagnostic Devices and Therapeutic Products                              | 25              |
| Novel Therapeutic Products  | 25              |
| Approval of a Therapeutic Product without an Approved IVD Companion Diagnostic Device                         | 25              |
| General Policies  | 26              |
| FDA-APPROVED COMPANION DIAGNOSTICS  | 27              |
| <i>TABLE 5 FDA-APPROVED IN VITRO COMPANION DIAGNOSTIC DEVICES AS OF DEC. 23, 2014</i>                         | 28              |
| <i>TABLE 6 FDA-APPROVED IN VITRO COMPANION DIAGNOSTIC DEVICES, AS OF DECEMBER 2012</i>                        | 34              |
| PHARMACOGENOMICS RESEARCH NETWORK   | 42              |
| <i>TABLE 7 CURRENT PGRN-RIKEN CGM COLLABORATIVE STUDIES</i>   | 43              |
| CHAPTER 5 COMMERCIAL MARKET TRENDS  | 50              |
| MARKET CONDITIONS   | 50              |
| HEALTHCARE, HOSPITALS, DOCTORS, GREATER REGULATION AND NEED FOR INSURANCE REIMBURSEMENT                       | 50              |
| NEW REQUIREMENTS FOR SUCCESS  | 50              |
| SALES AND MARKETING   | 50              |
| MEDICAL AFFAIRS   | 51              |
| REGULATORY COMPLIANCE   | 51              |
| REIMBURSEMENT   | 51              |
| ALLIANCES AND MERGERS   | 52              |
| <i>TABLE 8 DIAGNOSTICS MANUFACTURER MERGERS AND ACQUISITIONS, 2004-2014</i>                                   | 52              |
| CHAPTER 6 MARKET FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY  | 56              |
| OVERVIEW  | 56              |
| DESCRIPTION   | 56              |
| REVENUES AND FORECASTS  | 57              |
| <i>TABLE 9 GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)</i>              | 57              |
| <i>TABLE 10 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY, 2015 (%)</i>                         | 57              |
| <i>FIGURE 2 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY, 2015 (%)</i>                         | 57              |
| MANUFACTURERS   | 58              |
| <i>TABLE 11 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY MANUFACTURER, 2015 (%)</i>                       | 59              |
| <i>FIGURE 3 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY MANUFACTURER, 2015 (%)</i>                       | 59              |
| MICROARRAY  | 60              |
| DESCRIPTION   | 60              |
| Planar  | 60              |
| Bead  | 60              |
| REVENUES AND FORECASTS  | 61              |
| <i>TABLE 12 GLOBAL MICROARRAY MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i> | 61              |
| <i>TABLE 13 GLOBAL MICROARRAY MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>             | 62              |

| <b>TOPIC</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| <i>FIGURE 4 GLOBAL MICROARRAY MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                        | 62              |
| MANUFACTURERS AND PRODUCTS   | 63              |
| Planar   | 63              |
| <i>TABLE 14 MAJOR SUPPLIERS OF PLANAR DNA MICROARRAYS</i>  | 63              |
| Bead   | 64              |
| <i>TABLE 15 MAJOR SUPPLIERS OF BEAD MICROARRAYS</i>  | 64              |
| PCR  | 64              |
| DESCRIPTION  | 64              |
| REVENUES AND FORECASTS   | 65              |
| <i>TABLE 16 GLOBAL PCR MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>                   | 65              |
| <i>TABLE 17 GLOBAL PCR MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                               | 66              |
| <i>FIGURE 5 GLOBAL PCR MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                               | 66              |
| MANUFACTURERS AND PRODUCTS   | 66              |
| <i>TABLE 18 GLOBAL PCR MARKET SHARE BY MANUFACTURER, 2015 (%)</i>  | 67              |
| IN SITU HYBRIDIZATION (ISH)  | 67              |
| DESCRIPTION  | 67              |
| Labeling Techniques  | 68              |
| Applications of In Situ Hybridization  | 68              |
| FIBER FISH   | 69              |
| HER2 FISH TESTING  | 70              |
| REVENUES AND FORECASTS   | 71              |
| <i>TABLE 19 GLOBAL ISH MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>                   | 71              |
| <i>TABLE 20 GLOBAL ISH MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                               | 72              |
| <i>FIGURE 6 GLOBAL ISH MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                               | 72              |
| LAB-ON-A-CHIP/BIOCHIPS   | 72              |
| DESCRIPTION  | 72              |
| Microfluidic Devices   | 74              |
| PRODUCT DEVELOPMENT  | 75              |
| REVENUES AND FORECASTS   | 76              |
| <i>TABLE 21 GLOBAL LAB-ON-A-CHIP/BIOCHIP MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i> | 76              |
| <i>TABLE 22 GLOBAL LAB-ON-A-CHIP/BIOCHIP MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>             | 76              |
| <i>FIGURE 7 GLOBAL LAB-ON-A-CHIP/BIOCHIP MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>             | 77              |
| EMERGING AND OTHER DIAGNOSTIC TECHNOLOGIES   | 77              |
| DESCRIPTION  | 77              |
| The Trend toward Single-Cell Measurements  | 78              |
| Genetic Typing of Single Cells   | 78              |
| Single-Cell Sequencing   | 78              |
| Copy Number Variations in Single Cells   | 78              |
| Combined Immunotyping and Single-Cell Expression Analysis  | 78              |

| <b>TOPIC</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| Diagnosing the Epigenome   | 79              |
| REVENUES AND FORECASTS   | 79              |
| <i>TABLE 23 GLOBAL EMERGING/OTHER MOLECULAR DIAGNOSTICS MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>              | 79              |
| <i>TABLE 24 GLOBAL EMERGING/OTHER MOLECULAR DIAGNOSTICS MARKET SHARE BY APPLICATION, 2015 (%)</i>                          | 80              |
| CHAPTER 7 MARKETS FOR MOLECULAR DIAGNOSTICS BY APPLICATION AND PRODUCTS  | 82              |
| OVERVIEW   | 82              |
| DESCRIPTION  | 82              |
| REVENUES AND FORECASTS   | 82              |
| <i>TABLE 25 GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>                         | 82              |
| <i>TABLE 26 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                                     | 83              |
| <i>FIGURE 8 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                                     | 83              |
| PRE-/POSTNATAL GENETIC SCREENING   | 84              |
| DESCRIPTION  | 84              |
| Carrier Screening  | 84              |
| Prenatal Diagnostic Testing  | 85              |
| Amniocentesis  | 85              |
| Chorionic Villus Sampling  | 85              |
| Genetic Counseling   | 86              |
| Preimplantation Diagnosis  | 87              |
| Newborn Screening  | 87              |
| REVENUES AND FORECASTS   | 88              |
| <i>TABLE 27 GLOBAL PRE/POSTNATAL SCREENING MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i> | 88              |
| <i>TABLE 28 GLOBAL PRE/POSTNATAL SCREENING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>             | 88              |
| <i>FIGURE 9 GLOBAL PRE/POSTNATAL SCREENING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>             | 88              |
| INFECTIOUS DISEASE DIAGNOSTICS   | 89              |
| DESCRIPTION  | 89              |
| REVENUES AND FORECASTS   | 90              |
| <i>TABLE 29 GLOBAL INFECTIOUS DISEASES MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>     | 91              |
| <i>TABLE 30 GLOBAL INFECTIOUS DISEASE SCREENING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>        | 91              |
| <i>FIGURE 10 GLOBAL INFECTIOUS DISEASE SCREENIN MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>        | 91              |
| ONCOLOGY DIAGNOSTICS   | 92              |
| DESCRIPTION  | 92              |
| Leukemias  | 92              |
| Chronic Myeloid Leukemia   | 93              |
| Genetic Marker of Chronic Myeloid Leukemia   | 93              |
| REVENUES AND FORECASTS   | 94              |

| <b>TOPIC</b>  | <b>PAGE NO.</b> |
|---|-----------------|
| <i>TABLE 31 GLOBAL ONCOLOGY MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>                   | 94              |
| <i>TABLE 32 GLOBAL ONCOLOGY MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                               | 95              |
| <i>FIGURE 11 GLOBAL ONCOLOGY MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                              | 95              |
| IDENTITY DIAGNOSTICS, FORENSICS AND PATERNITY   | 95              |
| DESCRIPTION   | 95              |
| Paternity Testing   | 96              |
| Technology  | 96              |
| Accreditation   | 96              |
| Legal Issues  | 96              |
| Veterinary Identity Testing   | 97              |
| REVENUES AND FORECASTS  | 97              |
| <i>TABLE 33 GLOBAL IDENTITY TESTING MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>           | 98              |
| <i>TABLE 34 GLOBAL IDENTITY TESTING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                       | 98              |
| <i>FIGURE 12 GLOBAL IDENTITY TESTING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>                      | 98              |
| PHARMACOGENOMICS/OTHER APPLICATIONS   | 99              |
| DESCRIPTION   | 99              |
| REVENUES AND FORECASTS  | 102             |
| <i>TABLE 35 GLOBAL PHARMACOGENOMICS AND OTHER MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i> | 103             |
| <i>TABLE 36 GLOBAL PHARMACOGENOMICS AND OTHER MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)</i>             | 103             |
| CHAPTER 8 PATENT ANALYSIS   | 105             |
| PCR   | 105             |
| <i>TABLE 37 SELECTED PCR PATENTS GRANTED FROM JANUARY 2013 TO JANUARY 2015</i>  | 105             |
| REAL TIME PCR DETECTION OF RESPIRATORY SYNCYTIAL VIRUS  | 107             |
| NUCLEIC ACID AMPLIFICATION PRIMERS FOR PCR-BASED CLONALITY STUDIES  | 107             |
| QUANTITATIVE MULTIPLEX METHYLATION SPECIFIC PCR METHOD- CMETHODNA, REAGENTS, AND ITS USE                                      | 107             |
| REAL-TIME PCR DETECTION OF STREPTOCOCCUS PYOGENES   | 108             |
| REAL-TIME PCR FOR THE DETECTION OF PATHOGENS  | 108             |
| QUANTITATIVE MULTIPLEX METHYLATION-SPECIFIC PCR   | 109             |
| REAL-TIME PCR DETECTION OF MYCOBACTERIUM TUBERCULOSIS COMPLEX   | 109             |
| REAL TIME PCR DETECTION OF M. TUBERCULOSIS RESISTANT/SUSCEPTIBLE TO RIFAMPICIN AND/OR ISONIAZID                               | 109             |
| ABSOLUTE PCR QUANTIFICATION   | 110             |
| COMPOSITIONS AND METHOD FOR MEASURING AND CALIBRATING AMPLIFICATION BIAS IN MULTIPLEXED PCR REACTIONS                         | 110             |
| REAL-TIME PCR DETECTION OF SEASONAL INFLUENZA H1, H3 AND B SUBTYPES   | 110             |
| MULTIMODAL PCR TARGET DETECTION   | 111             |
| COMPOSITION TO OVERCOME INHIBITORS IN PCR AND GROWTH CULTURES   | 111             |
| MAGNETIC IMMUNO DIGITAL PCR ASSAY   | 111             |
| CUTOFF POINT DELTA CT. METHOD FOR HER2 PCR TESTING IN BREAST CANCER   | 112             |

| <b>TOPIC</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| METHODS AND COMPOSITIONS FOR PCR USING BLOCKED AND UNIVERSAL PRIMERS   | 112             |
| PCR ASSAYS AND REAGENTS FOR MOLECULAR DETECTION OF INFECTIOUS AGENTS   | 112             |
| RANDOM HOMOZYGOUS GENE PERTURBATION (RHGP) WITH THERMAL ASSYMETRIC INTERLACED (TAIL)-PCR   | 113             |
| MICRO RNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF OVARIAN CANCER USING A REAL-TIME PCR PLATFORM                                   | 113             |
| PCR METHODS FOR CHARACTERIZING THE 5' UNTRANSLATED REGION OF THE FMR1 AND FMR2 GENES   | 114             |
| MULTIPLEX PCR-BASED TESTING OF CUTANEOUS SQUAMOUS CELL CARCINOMA AND PSEUDOEPITHELIOMATOUS HYPERPLASIA AND METHODS FOR DISTINGUISHING THE SAME                         | 114             |
| IDENTIFICATION OF ANTIGEN-SPECIFIC ADAPTIVE IMMUNE RESPONSES USING ARM-PCR AND HIGH-THROUGHPUT SEQUENCING  | 114             |
| QUANTITATIVE MULTIPLEX METHYLATION-SPECIFIC PCR  | 115             |
| PCR DIAGNOSTICS OF DERMATOPHYTES AND OTHER PATHOGENIC FUNGI  | 115             |
| HIGHLY MULTIPLEX PCR METHODS AND COMPOSITIONS  | 115             |
| SINGLE TUBE QUANTITATIVE POLYMERASE CHAIN REACTION (PCR)   | 116             |
| HIGHLY MULTIPLEX PCR METHODS AND COMPOSITIONS  | 116             |
| IDENTIFICATION OF LINKAGE USING MULTIPLEX DIGITAL PCR  | 116             |
| METHODS AND COMPOSITIONS TO ENABLE MULTIPLEX COLD-PCR  | 117             |
| METHODS OF DIAGNOSING DISEASE USING OVERLAP EXTENSION PCR  | 117             |
| HOT-START DIGITAL PCR  | 117             |
| METHOD FOR DETECTION, DIFFERENTIATION AND QUANTIFICATION OF T CELL POPULATIONS BY WAY OF REVERSE TRANSCRIPTION QUANTITATIVE REAL TIME PCR (RT-QPCR) TECHNOLOGY         | 118             |
| NDM-1 POLYMERASE CHAIN REACTION (PCR) ASSAY  | 118             |
| DETECTION OF MICRO METASTASIS OF MELANOMA AND BREAST CANCER IN PARAFFIN-EMBEDDED TUMOR DRAINING LYMPH NODES BY MULTIMARKER QUANTITATIVE RT-PCR                         | 118             |
| LATE-PCR   | 119             |
| HEMOMOSAIC: HIGH-THROUGHPUT TECHNIQUE FOR RARE CELL DETECTION IN LIQUID SAMPLES BY MASSIVELY MULTIPLEXED PCR IN A PHOTOLITHOGRAPHIC MATRIX                             | 119             |
| SERIAL QUANTITATIVE PCR ASSAY FOR DETECTION, SPECIES-DISCRIMINATION AND QUANTIFICATION OF LEISHMANIA SPP. IN HUMAN SAMPLES   | 120             |
| GENE DETECTING METHODS WITHOUT USING PCR   | 120             |
| HIGHLY MULTIPLEX PCR METHODS AND COMPOSITIONS  | 120             |
| PROCESS FOR DETECTION OF MULTIDRUG RESISTANT TUBERCULOSIS USING REAL-TIME PCR AND HIGH RESOLUTION MELT ANALYSIS  | 121             |
| ISOFORMS OF THE HUMAN SST5 RECEPTOR ORIGINATED BY ALTERNATIVE SPLICING AND OLIGONUCLEOTIDE PAIRS TO DETECT THEM BY PCR   | 121             |
| REAL TIME PCR ASSAY FOR DETECTION OF BACTERIAL RESPIRATORY PATHOGENS   | 121             |
| METHODS AND COMPOSITIONS RELATED TO CONTINUOUS FLOW THERMAL GRADIENT PCR   | 122             |
| METHOD FOR DETECTING MORE THAN ONE TARGET IN A PCR-BASED APPROACH APPLYING AN UN-SPECIFIC DYE WHICH IS NOT INTERFERING WITH THE EMISSION OF FLUOROPHORE-LABELED PROBES | 122             |
| MICROARRAY   | 123             |

| <b>TOPIC</b>  | <b>PAGE NO.</b> |
|---|-----------------|
| <i>TABLE 38 SELECTED MICROARRAY PATENTS GRANTED, JANUARY 2013 TO MAY 2015</i>   | 123             |
| METHODS AND SYSTEMS FOR MANUFACTURE OF MICROARRAY ASSAY SYSTEMS, CONDUCTING MICROFLUIDIC ASSAYS, AND MONITORING AND SCANNING TO OBTAIN MICROFLUIDIC ASSAY RESULTS       | 124             |
| SYMMETRICALLY BRANCHED POLYMER CONJUGATES AND MICROARRAY ASSAYS   | 124             |
| TWO-DIMENSIONAL PHOTONIC CRYSTAL MICROARRAY MEASUREMENT METHOD AND APPARATUS FOR HIGHLY-SENSITIVE LABEL-FREE MULTIPLE ANALYTE SENSING, BIOSENSING, AND DIAGNOSTIC ASSAY | 124             |
| SOURCE CONTROLLED DECODABLE MICROARRAY SYSTEM AND METHODS FOR USE   | 125             |
| MICROARRAY BASED SAMPLE DETECTION SYSTEM  | 125             |
| MICROARRAY FABRICATION SYSTEM AND METHOD  | 125             |
| MICROARRAY FOR DETECTING VIABLE ORGANISMS   | 126             |
| SERUM-BASED MIRNA MICROARRAY AND ITS USE IN DIAGNOSIS AND TREATMENT OF BARRETT'S ESOPHAGUS (BE) AND ESOPHAGEAL ADENOCARCINOMA (EAC)                                     | 126             |
| LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS  | 126             |
| Y-SHAPED PROBE AND VARIANT THEREOF, AND DNA MICROARRAY, KIT AND GENETIC ANALYSIS METHOD USING THE SAME  | 127             |
| MICROARRAY-BASED ASSAY INTEGRATED WITH PARTICLES FOR ANALYZING MOLECULAR INTERACTIONS   | 127             |
| MICROARRAY FABRICATION SYSTEM AND METHOD  | 128             |
| ALLERGEN MICROARRAY   | 128             |
| PHOTONIC CRYSTAL MICROARRAY LAYOUTS FOR ENHANCED SENSITIVITY AND SPECIFICITY OF LABEL-FREE MULTIPLE ANALYTE SENSING, BIOSENSING AND DIAGNOSTIC ASSAY                    | 128             |
| ISH   | 129             |
| <i>TABLE 39 SELECTED ISH PATENTS GRANTED, JANUARY 2013 TO MAY 2015</i>  | 129             |
| CELL PREPARATIONS AND CELL SUPPORTS AND THEIR USE IN THERANOSIS   | 129             |
| ULTRA SENSITIVE METHOD FOR IN SITU DETECTION OF NUCLEIC ACIDS   | 129             |
| BACH2 REPRESSION IN CELLS   | 130             |
| IN SITU HYBRIDIZATION METHOD AND BUFFER   | 130             |
| BIOCHIP   | 131             |
| <i>TABLE 40 SELECTED BIOCHIP PATENTS GRANTED, JANUARY 2013 TO MAY 2015</i>  | 131             |
| BIOCHIP AND TARGET DNA QUANTITATIVE METHOD  | 131             |
| UNITARY BIOCHIP PROVIDING SAMPLE-IN TO RESULTS-OUT PROCESSING AND METHODS OF MANUFACTURE  | 132             |
| BIOCHIP AND FABRICATION THEREOF   | 132             |
| UNITARY BIOCHIP PROVIDING SAMPLE-IN TO RESULTS-OUT PROCESSING AND METHODS OF MANUFACTURE  | 132             |
| BIOCHIP ASSEMBLY AND ASSAY METHOD THEREOF   | 133             |
| BIOCHIP   | 133             |
| CHAPTER 9 COMPANY PROFILES  | 135             |
| ABBOTT MOLECULAR  | 135             |
| PRODUCT CATEGORIES  | 136             |
| PARTNERSHIPS  | 136             |
| ADVANDX INC.  | 136             |



| <b>TOPIC</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| AFFYMETRIX INC.  | 137             |
| PRODUCTS   | 138             |
| Agrigenomics Genotyping Solutions                        | 138             |
| Chromogenic RNA in situ Hybridization                    | 138             |
| Fluorescence RNA in situ Hybridization                   | 139             |
| AGILENT TECHNOLOGIES INC.                                | 139             |
| PRODUCTS   | 140             |
| PCR/qPCR   | 140             |
| AUTOGENOMICS INC.  | 142             |
| PRODUCTS   | 143             |
| BECKMAN COULTER INC. (OWNED BY DANAHER)                  | 143             |
| PRODUCTS   | 144             |
| Pipeline   | 144             |
| BECTON DICKINSON AND COMPANY                             | 144             |
| BIOMERIEUX SA  | 145             |
| PRODUCTS   | 147             |
| Argene Molecular Biology Range                           | 147             |
| BIO-RAD LABORATORIES                                     | 148             |
| LIFE SCIENCE RESEARCH                                    | 148             |
| CLINICAL DIAGNOSTICS                                     | 149             |
| PRODUCTS   | 149             |
| Amplification/PCR  | 149             |
| Digital PCR  | 149             |
| PrimePCR Assays and Panels                               | 149             |
| Real-Time PCR Detection Systems                          | 149             |
| Thermal Cyclers  | 149             |
| PX1 PCR Plate Sealer                                     | 149             |
| PCR Reagents   | 150             |
| PCR Plastic Consumables                                  | 150             |
| Amplification Software                                   | 150             |
| Nucleic Acid Sample Preparation and Purification         | 150             |
| CALIPER LIFE SCIENCES INC.                               | 150             |
| PRODUCTS   | 151             |
| Microfluidics, Laboratory Automation and Liquid Handling | 151             |
| THE CARLYLE GROUP  | 151             |
| CEPHEID  | 152             |
| PRODUCTS   | 153             |
| CURAGEN CORP. (ACQUIRED BY CELLDLEX)                     | 154             |
| DECODE GENETICS  | 154             |
| PRODUCTS AND SERVICES                                    | 155             |
| DNA DIAGNOSTICS CENTER                                   | 155             |
| SERVICES   | 155             |
| ELITECH GROUP  | 157             |
| EMD MILLIPORE  | 157             |
| PRODUCTS   | 158             |
| EUROGENTEC (OWNED BY KANEKA CORP.)                       | 158             |
| PRODUCTS   | 159             |

| TOPIC  | PAGE NO. |
|--|----------|
| SERVICES   | 159      |
| EXACT SCIENCES CORP.   | 160      |
| GE HEALTHCARE  | 160      |
| HOLOGIC INC.   | 161      |
| PRODUCTS   | 162      |
| HTG MOLECULAR DIAGNOSTICS  | 163      |
| SERVICES   | 164      |
| PRODUCTS   | 164      |
| ILLUMINA   | 164      |
| PRODUCTS   | 165      |
| LABORATORY CORP. OF AMERICA (LABCORP)  | 165      |
| LIFE TECHNOLOGIES  | 166      |
| PRODUCTS   | 166      |
| LUMINEX CORP   | 167      |
| PRODUCTS   | 167      |
| xMAP technology  | 167      |
| xTAG Technology  | 168      |
| MultiCode Technology   | 168      |
| MICRONICS INC.   | 168      |
| PRODUCTS   | 169      |
| MYRIAD GENETICS  | 169      |
| PRODUCTS   | 170      |
| PRODUCTS IN DEVELOPMENT  | 171      |
| NOVARTIS MOLECULAR DIAGNOSTICS   | 171      |
| PRODUCTS   | 172      |
| Development Strategy   | 172      |
| Novartis Diagnostics Division Products   | 172      |
| OXFORD GENE TECHNOLOGY IP LTD.   | 173      |
| PRODUCTS   | 173      |
| PATHOGENETIX   | 174      |
| PROMEGA  | 175      |
| QIAGEN N.V.  | 176      |
| PRODUCTS   | 176      |
| COMPANION DIAGNOSTICS  | 177      |
| QUEST DIAGNOSTICS  | 178      |
| PRODUCTS   | 178      |
| IN DEVELOPMENT   | 178      |
| ROCHE  | 179      |
| <i>TABLE 41 ROCHE-COMPANION DIAGNOSTICS PIPELINE JOINT ONCOLOGY PHARMA AND DIAGNOSTICS</i> | 181      |
| SAVYON DIAGNOSTICS   | 181      |
| PRODUCTS   | 181      |
| SEQUENOM INC.  | 182      |
| PRODUCTS   | 183      |
| APPLICATIONS   | 183      |
| SIEMENS  | 184      |
| SORENSEN GENOMICS INC.   | 185      |
| THERMO FISHER SCIENTIFIC INC.  | 185      |

| <b>TOPIC</b>             | <b>PAGE NO.</b> |
|--------------------------|-----------------|
| TRANSGENOMIC INC.        | 186             |
| PRODUCTS AND PIPELINES   | 187             |
| Genetic Testing Services | 187             |
| In Development           | 188             |

**LIST OF TABLES**

| <b>TABLE HEADING</b>  | <b>PAGE NO.</b> |
|---|-----------------|
| SUMMARY TABLE GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)                     | 6               |
| TABLE 1 MINIMUM INFORMATION ABOUT A MICROARRAY EXPERIMENT - MIAME 2.0   | 18              |
| TABLE 2 MICROARRAY QUALITY CONTROL (MAQC) PROJECT   | 19              |
| TABLE 3 U.S. LABORATORIES CLIA-CERTIFIED FOR MOLECULAR DIAGNOSTICS AND NUMBER OF DISEASE TESTS, 2012                | 21              |
| TABLE 4 GENETIC TESTING PROCEDURES PERFORMED IN U.S. BY TYPE, 2015  | 22              |
| TABLE 5 FDA-APPROVED IN VITRO COMPANION DIAGNOSTIC DEVICES AS OF DEC. 23, 2014                                      | 28              |
| TABLE 6 FDA-APPROVED IN VITRO COMPANION DIAGNOSTIC DEVICES, AS OF DECEMBER 2012                                     | 34              |
| TABLE 7 CURRENT PGRN-RIKEN CGM COLLABORATIVE STUDIES  | 43              |
| TABLE 8 DIAGNOSTICS MANUFACTURER MERGERS AND ACQUISITIONS, 2004-2014  | 52              |
| TABLE 9 GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)                           | 57              |
| TABLE 10 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY, 2015 (%)                                      | 57              |
| TABLE 11 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY MANUFACTURER, 2015 (%)                                    | 59              |
| TABLE 12 GLOBAL MICROARRAY MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)              | 61              |
| TABLE 13 GLOBAL MICROARRAY MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                          | 62              |
| TABLE 14 MAJOR SUPPLIERS OF PLANAR DNA MICROARRAYS  | 63              |
| TABLE 15 MAJOR SUPPLIERS OF BEAD MICROARRAYS  | 64              |
| TABLE 16 GLOBAL PCR MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)                     | 65              |
| TABLE 17 GLOBAL PCR MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                                 | 66              |
| TABLE 18 GLOBAL PCR MARKET SHARE BY MANUFACTURER, 2015 (%)  | 67              |
| TABLE 19 GLOBAL ISH MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)                     | 71              |
| TABLE 20 GLOBAL ISH MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                                 | 72              |
| TABLE 21 GLOBAL LAB-ON-A-CHIP/BIOCHIP MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)   | 76              |
| TABLE 22 GLOBAL LAB-ON-A-CHIP/BIOCHIP MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)               | 76              |
| TABLE 23 GLOBAL EMERGING/OTHER MOLECULAR DIAGNOSTICS MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)              | 79              |
| TABLE 24 GLOBAL EMERGING/OTHER MOLECULAR DIAGNOSTICS MARKET SHARE BY APPLICATION, 2015 (%)                          | 80              |
| TABLE 25 GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)                         | 82              |
| TABLE 26 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                                     | 83              |
| TABLE 27 GLOBAL PRE/POSTNATAL SCREENING MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS) | 88              |
| TABLE 28 GLOBAL PRE/POSTNATAL SCREENING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)             | 88              |

| <b>TABLE HEADING</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| TABLE 29 GLOBAL INFECTIOUS DISEASES MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)        | 91              |
| TABLE 30 GLOBAL INFECTIOUS DISEASE SCREENING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)           | 91              |
| TABLE 31 GLOBAL ONCOLOGY MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)                   | 94              |
| TABLE 32 GLOBAL ONCOLOGY MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                               | 95              |
| TABLE 33 GLOBAL IDENTITY TESTING MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)           | 98              |
| TABLE 34 GLOBAL IDENTITY TESTING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                       | 98              |
| TABLE 35 GLOBAL PHARMACOGENOMICS AND OTHER MARKET FOR MOLECULAR DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS) | 103             |
| TABLE 36 GLOBAL PHARMACOGENOMICS AND OTHER MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)             | 103             |
| TABLE 37 SELECTED PCR PATENTS GRANTED FROM JANUARY 2013 TO JANUARY 2015  | 105             |
| TABLE 38 SELECTED MICROARRAY PATENTS GRANTED, JANUARY 2013 TO MAY 2015   | 123             |
| TABLE 39 SELECTED ISH PATENTS GRANTED, JANUARY 2013 TO MAY 2015  | 129             |
| TABLE 40 SELECTED BIOCHIP PATENTS GRANTED, JANUARY 2013 TO MAY 2015  | 131             |
| TABLE 41 ROCHE-COMPANION DIAGNOSTICS PIPELINE JOINT ONCOLOGY PHARMA AND DIAGNOSTICS                                    | 181             |

**LIST OF FIGURES**

| <b>FIGURE TITLE</b>   | <b>PAGE NO.</b> |
|---|-----------------|
| SUMMARY FIGURE GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY, 2012-2020 (\$ MILLIONS)                 | 6               |
| FIGURE 1 GROWTH IN CLINICAL LABORATORY SITES AND DISEASE TESTING, 1993-2015                                   | 21              |
| FIGURE 2 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY TECHNOLOGY, 2015 (%)                                | 57              |
| FIGURE 3 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY MANUFACTURER, 2015 (%)                              | 59              |
| FIGURE 4 GLOBAL MICROARRAY MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                    | 62              |
| FIGURE 5 GLOBAL PCR MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                           | 66              |
| FIGURE 6 GLOBAL ISH MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                           | 72              |
| FIGURE 7 GLOBAL LAB-ON-A-CHIP/BIOCHIP MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)         | 77              |
| FIGURE 8 GLOBAL MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                               | 83              |
| FIGURE 9 GLOBAL PRE/POSTNATAL SCREENING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)       | 88              |
| FIGURE 10 GLOBAL INFECTIOUS DISEASE SCREENING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%) | 91              |
| FIGURE 11 GLOBAL ONCOLOGY MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)                     | 95              |
| FIGURE 12 GLOBAL IDENTITY TESTING MARKET SHARE FOR MOLECULAR DIAGNOSTICS BY APPLICATION, 2015 (%)             | 98              |